23.68

4.05% -1.00

After Hours: 23.75 0.07 +0.30%

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $23.68, with a volume of 3.80M. It is down -4.05% in the last 24 hours and up +3.72% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Previous Close:

$24.68

Open:

$24.5

24h Volume:

3.80M

Relative Volume:

1.50

Market Cap:

$3.01B

Revenue:

$642.82M

Net Income/Loss:

$-43.54M

P/E Ratio:

-67.73

EPS:

-0.3496

Net Cash Flow:

$130.12M

1W Performance:

+11.70%

1M Performance:

+3.72%

6M Performance:

+29.12%

1Y Performance:

+177.28%

1-Day Range:

$23.43

$25.23

1-Week Range:

$20.88

$25.23

52-Week Range:

$8.065

$26.45

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1108)

Industry

Health Information Services (49)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,178

Twitter

@10xgenomics

Next Earnings Date

2026-05-07

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	23.68	3.13B	642.82M	-43.54M	130.12M	-0.3496
VEEV Veeva Systems Inc	160.17	25.83B	3.20B	908.91M	1.39B	5.4168
BTSG Brightspring Health Services Inc	58.50	11.25B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	46.18	8.35B	1.36B	-302.91M	-219.93M	-1.7182
HQY Healthequity Inc	88.11	7.25B	1.31B	215.20M	408.32M	2.4627
HNGE Hinge Health Inc	55.25	4.27B	646.34M	-512.40M	202.76M	-6.6871

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-26	Upgrade	William Blair	Mkt Perform → Outperform
Dec-11-25	Downgrade	Citigroup	Buy → Neutral
Dec-02-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-11-25	Initiated	Piper Sandler	Neutral
Feb-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

May 20, 2026

The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call - Yahoo Finance

May 18, 2026

May 17, 2026

10x Genomics Q1 earnings call highlights - MSN

May 17, 2026

The Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance - Sahm

May 17, 2026

May 16, 2026

Precision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders Daily

May 16, 2026

May 15, 2026

TXG Technical Analysis & Stock Price Forecast - Intellectia AI

May 15, 2026

May 14, 2026

10x Genomics seen as key player in AI-driven biological data buildout - MSN

May 14, 2026

Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results - Sahm

May 14, 2026

May 13, 2026

QUADRANT CAPITAL GROUP LLC's 10x Genomics Inc(TXG) Holding History - GuruFocus

May 13, 2026

May 12, 2026

Why 10x Genomics (TXG) Stock Is Down Today - Yahoo Finance

May 12, 2026